Product How it works Pricing Blog FAQ About Contact
United States

Relay Therapeutics (NASDAQ: RLAY) stock: the official figures

Relay Therapeutics (RELAY THERAPEUTICS, INC.) is listed on Nasdaq under the ticker RLAY and belongs to the health care sector. In fiscal 2025 it reported revenue of $15.4m and a net loss of $276.5m, according to the annual accounts it filed with the regulator.

Identifiers for Relay Therapeutics: SEC CIK 1812364.

Fiscal 2025 figures

Consolidated annual accounts of Relay Therapeutics, in millions of US dollars
Item20252024Change
Revenue$15.4m$10.0m+53.4%
Operating profit−$302.7m−$372.5m—
Net profit−$276.5m−$337.7m—
Earnings per share−$1.61−$2.36—
Operating margin−1,971.6%−3,722.1%+1,750.5 pts
Net margin−1,800.6%−3,374.7%+1,574.1 pts
Total assets$621.3m$871.3m−28.7%
Equity$567.1m$777.8m−27.1%
Cash$84.0m$124.3m−32.4%
Operating cash flow−$235.5m−$249.1m—

Margins are calculated from the filed figures: operating profit and net profit over revenue.

7 fiscal years

Revenue, in millions of US dollars82.720203.020211.4202225.5202310.0202415.42025Net profit, in millions of US dollars-75.32019-52.42020-363.92021-290.52022-342.02023-337.72024-276.52025
Fiscal yearRevenueOperating profitNet profitEarnings per shareDocument
2025$15.4m−$302.7m−$276.5m−$1.61Annual report
2024$10.0m−$372.5m−$337.7m−$2.36Annual report
2023$25.5m−$373.0m−$342.0m−$2.79Annual report
2022$1.4m−$299.3m−$290.5m−$2.59Annual report
2021$3.0m−$364.7m−$363.9m−$3.82Annual report
2020$82.7m−$55.8m−$52.4m−$5.40Annual report
2019—−$84.0m−$75.3m—Annual report

The full income statement, balance sheet and cash flow statement are in the annual accounts of Relay Therapeutics. Purchases and sales by its executives and directors are in insider transactions.

Frequently asked questions about Relay Therapeutics

How much did Relay Therapeutics earn in fiscal 2025?
Relay Therapeutics reported a net loss of $276.5m for fiscal 2025, on revenue of $15.4m. The year before it reported a net loss of $337.7m.
What are the earnings per share of Relay Therapeutics?
They were −$1.61 in fiscal 2025, compared with −$2.36 the year before.
Where is Relay Therapeutics listed?
Relay Therapeutics is listed on Nasdaq under the ticker RLAY and belongs to the health care sector.
Where do the figures for Relay Therapeutics come from?
From the annual report (Form 10-K) that Relay Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

The annual accounts come from the annual report (Form 10-K) that Relay Therapeutics files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.